The University of Chicago Header Logo

Connection

Issam Awad to Hemangioma, Cavernous, Central Nervous System

This is a "connection" page, showing publications Issam Awad has written about Hemangioma, Cavernous, Central Nervous System.
  1. Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo. J Am Heart Assoc. 2026 02 03; 15(3):e46943.
    View in: PubMed
    Score: 0.723
  2. Relevance of Lesion Volume as an Outcome in Cerebral Cavernous Malformation Drug Trial: Exploratory Analyses in Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept. Neurosurgery. 2026 Jun 01; 98(6):1395-1401.
    View in: PubMed
    Score: 0.710
  3. Identifying features of prior hemorrhage in cerebral cavernous malformations on quantitative susceptibility maps: a machine learning pilot study. J Neurosurg. 2025 Dec 01; 143(6):1567-1574.
    View in: PubMed
    Score: 0.695
  4. A Systematic Review of MicroRNAs in Hemorrhagic Neurovascular Disease: Cerebral Cavernous Malformations as a Paradigm. Int J Mol Sci. 2025 Apr 17; 26(8).
    View in: PubMed
    Score: 0.685
  5. Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. Lancet Neurol. 2025 Apr; 24(4):295-304.
    View in: PubMed
    Score: 0.683
  6. Circulating molecules reflect imaging biomarkers of hemorrhage in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2025 06; 45(6):1153-1165.
    View in: PubMed
    Score: 0.674
  7. Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations. Transl Stroke Res. 2025 Jun; 16(3):859-867.
    View in: PubMed
    Score: 0.649
  8. Transcriptomic signatures of individual cell types in cerebral cavernous malformation. Cell Commun Signal. 2024 01 09; 22(1):23.
    View in: PubMed
    Score: 0.627
  9. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling. Stroke. 2024 01; 55(1):31-39.
    View in: PubMed
    Score: 0.625
  10. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome. Stroke. 2024 01; 55(1):22-30.
    View in: PubMed
    Score: 0.625
  11. Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation. J Stroke Cerebrovasc Dis. 2023 Jul; 32(7):107167.
    View in: PubMed
    Score: 0.598
  12. Credulity of exploratory trials for cerebral cavernous malformations. Lancet Neurol. 2023 01; 22(1):2-3.
    View in: PubMed
    Score: 0.579
  13. Propranolol as therapy for cerebral cavernous malformations: a cautionary note. J Transl Med. 2022 04 05; 20(1):160.
    View in: PubMed
    Score: 0.555
  14. Commentary: Feasibility and Morbidity of Magnetic Resonance Imaging-Guided Stereotactic Laser Ablation of Deep Cerebral Cavernous Malformations: A Report of 4 Cases. Neurosurgery. 2021 09 15; 89(4):E207-E208.
    View in: PubMed
    Score: 0.534
  15. COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
    View in: PubMed
    Score: 0.533
  16. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
    View in: PubMed
    Score: 0.513
  17. Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 02 01; 131(3).
    View in: PubMed
    Score: 0.512
  18. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
    View in: PubMed
    Score: 0.403
  19. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging. 2018 04; 47(4):1133-1138.
    View in: PubMed
    Score: 0.402
  20. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
    View in: PubMed
    Score: 0.383
  21. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
    View in: PubMed
    Score: 0.375
  22. Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease. J Neurosci Methods. 2016 09 15; 271:14-24.
    View in: PubMed
    Score: 0.372
  23. B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. J Neuroimmune Pharmacol. 2016 06; 11(2):369-77.
    View in: PubMed
    Score: 0.367
  24. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. AJNR Am J Neuroradiol. 2016 Jul; 37(7):1209-15.
    View in: PubMed
    Score: 0.364
  25. Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64.
    View in: PubMed
    Score: 0.362
  26. Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
    View in: PubMed
    Score: 0.344
  27. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med. 2015 Mar; 17(3):188-196.
    View in: PubMed
    Score: 0.327
  28. Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. J Neuroimmunol. 2014 Jul 15; 272(1-2):67-75.
    View in: PubMed
    Score: 0.321
  29. Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations. Stroke. 2014 Feb; 45(2):598-601.
    View in: PubMed
    Score: 0.311
  30. Cavernous malformations. J Neurosurg. 2012 Jan; 116(1):119-20; discussion 121.
    View in: PubMed
    Score: 0.268
  31. Fatal "hypertensive" intracerebral hemorrhage associated with a cerebral cavernous angioma: case report. Acta Neurochir (Wien). 2011 Feb; 153(2):421-3.
    View in: PubMed
    Score: 0.249
  32. Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution. Neurosurg Focus. 2010 Sep; 29(3):E4.
    View in: PubMed
    Score: 0.249
  33. Emerging clinical imaging techniques for cerebral cavernous malformations: a systematic review. Neurosurg Focus. 2010 Sep; 29(3):E6.
    View in: PubMed
    Score: 0.249
  34. Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions. Neurosurgery. 2008 Oct; 63(4):782-9; discussion 789.
    View in: PubMed
    Score: 0.218
  35. Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery. 2008 Oct; 63(4):790-7; discussion 797-8.
    View in: PubMed
    Score: 0.218
  36. Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. J Neurosurg. 2007 Nov; 107(5):1023-6.
    View in: PubMed
    Score: 0.204
  37. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery. 2006 Dec; 59(6):1278-84; discussion 1284-5.
    View in: PubMed
    Score: 0.192
  38. Growth of PIK3CA-driven cerebral cavernous malformations does not require microbiome stimulation. JCI Insight. 2026 Sep 08; 11(17).
    View in: PubMed
    Score: 0.187
  39. Cerebral cavernous malformations: clinical insights from genetic studies. Neurosurg Focus. 2006 Jul 15; 21(1):e1.
    View in: PubMed
    Score: 0.187
  40. Cerebral cavernous malformations and epilepsy. Neurosurg Focus. 2006 Jul 15; 21(1):e7.
    View in: PubMed
    Score: 0.187
  41. TIE2 links MEKK3-KLF2/4 and PI3K signaling in cerebral cavernous malformation. J Exp Med. 2026 May 04; 223(5).
    View in: PubMed
    Score: 0.183
  42. Recurrent somatic copy number alterations in resected cerebral cavernous malformations. Hum Genomics. 2025 12 09; 20(1):12.
    View in: PubMed
    Score: 0.179
  43. Association of Quality of Life Domains and Clinical Symptoms in Patients With Familial Cerebral Cavernous Malformation. J Am Heart Assoc. 2025 09 02; 14(17):e035926.
    View in: PubMed
    Score: 0.176
  44. Guidelines for the Diagnosis and Clinical Management of Cavernous Malformations of the Brain and Spinal Cord: Consensus Recommendations Based on a Systematic Literature Review by the Alliance to Cure Cavernous Malformation Clinical Advisory Board Experts Panel. Neurosurgery. 2026 Jan 01; 98(1):3-22.
    View in: PubMed
    Score: 0.172
  45. Intracranial cavernous angioma: a practical review of clinical and biological aspects. Surg Neurol. 2005 Apr; 63(4):319-28; discussion 328.
    View in: PubMed
    Score: 0.171
  46. Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke. 2005 Apr; 36(4):872-4.
    View in: PubMed
    Score: 0.169
  47. Multiple spinal cavernous malformations with atypical phenotype after prior irradiation: case report. Neurosurgery. 2004 Dec; 55(6):1431.
    View in: PubMed
    Score: 0.167
  48. Epigenetic regulation by polycomb repressive complex 1 promotes cerebral cavernous malformations. EMBO Mol Med. 2024 11; 16(11):2827-2855.
    View in: PubMed
    Score: 0.165
  49. Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling. Arterioscler Thromb Vasc Biol. 2024 06; 44(6):1246-1264.
    View in: PubMed
    Score: 0.160
  50. Antithrombotic Therapy in Cerebral Cavernous Malformations: A Systematic Review, Meta-Analysis, and Network Meta-Analysis. J Am Heart Assoc. 2024 03 19; 13(6):e032910.
    View in: PubMed
    Score: 0.159
  51. Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations. Nat Commun. 2023 11 02; 14(1):7009.
    View in: PubMed
    Score: 0.155
  52. mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice. Stroke. 2023 11; 54(11):2906-2917.
    View in: PubMed
    Score: 0.154
  53. ß1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations. FASEB J. 2022 12; 36(12):e22629.
    View in: PubMed
    Score: 0.145
  54. Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2023 08; 14(4):513-529.
    View in: PubMed
    Score: 0.141
  55. Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project. Stroke. 2021 12; 52(12):3829-3838.
    View in: PubMed
    Score: 0.134
  56. Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. J Clin Invest. 2021 07 01; 131(13).
    View in: PubMed
    Score: 0.132
  57. Cerebral Cavernous Malformation: From Mechanism to Therapy. Circ Res. 2021 06 25; 129(1):195-215.
    View in: PubMed
    Score: 0.131
  58. Abortive intussusceptive angiogenesis causes multi-cavernous vascular malformations. Elife. 2021 05 20; 10.
    View in: PubMed
    Score: 0.131
  59. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
    View in: PubMed
    Score: 0.130
  60. Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. J Exp Med. 2020 10 05; 217(10).
    View in: PubMed
    Score: 0.125
  61. Novel Murine Models of Cerebral Cavernous Malformations. Angiogenesis. 2020 11; 23(4):651-666.
    View in: PubMed
    Score: 0.123
  62. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. 2020 10; 42(5):1351-1363.
    View in: PubMed
    Score: 0.122
  63. Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. J Autoimmun. 2020 09; 113:102469.
    View in: PubMed
    Score: 0.121
  64. Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2021 03 01; 134(3):1147-1154.
    View in: PubMed
    Score: 0.121
  65. Stereotactic laser interstitial thermal therapy for epilepsy associated with solitary and multiple cerebral cavernous malformations. Neurosurg Focus. 2020 04 01; 48(4):E12.
    View in: PubMed
    Score: 0.121
  66. Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. Int J Mol Sci. 2020 Jan 20; 21(2).
    View in: PubMed
    Score: 0.119
  67. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
    View in: PubMed
    Score: 0.118
  68. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med. 2019 11 27; 11(520).
    View in: PubMed
    Score: 0.118
  69. Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathol Commun. 2019 08 19; 7(1):132.
    View in: PubMed
    Score: 0.116
  70. A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasis. Nat Commun. 2019 04 17; 10(1):1791.
    View in: PubMed
    Score: 0.113
  71. Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. 2019 04 01; 84(4):954-964.
    View in: PubMed
    Score: 0.113
  72. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
    View in: PubMed
    Score: 0.112
  73. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. 2019 01 17; 133(3):193-204.
    View in: PubMed
    Score: 0.110
  74. The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation. FASEB J. 2019 02; 33(2):2132-2143.
    View in: PubMed
    Score: 0.109
  75. Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest. 2019 03; 99(3):319-330.
    View in: PubMed
    Score: 0.107
  76. Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
    View in: PubMed
    Score: 0.106
  77. Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. J Exp Med. 2017 Nov 06; 214(11):3331-3346.
    View in: PubMed
    Score: 0.101
  78. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017 05 18; 545(7654):305-310.
    View in: PubMed
    Score: 0.099
  79. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016 Apr 07; 532(7597):122-6.
    View in: PubMed
    Score: 0.091
  80. Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping. Invest Radiol. 2014 Jul; 49(7):498-504.
    View in: PubMed
    Score: 0.081
  81. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum Mol Genet. 2014 Aug 15; 23(16):4357-70.
    View in: PubMed
    Score: 0.080
  82. Magnetic resonance imaging evaluation of cerebral cavernous malformations with susceptibility-weighted imaging. Neurosurgery. 2011 Mar; 68(3):641-7; discussion 647-8.
    View in: PubMed
    Score: 0.064
  83. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet. 2011 Jan 15; 20(2):211-22.
    View in: PubMed
    Score: 0.063
  84. Brainstem cavernous malformations. Neurosurgery. 2009 May; 64(5):E805-18; discussion E818.
    View in: PubMed
    Score: 0.057
  85. What genes can teach us about human cerebrovascular malformations. Clin Neurosurg. 2004; 51:140-52.
    View in: PubMed
    Score: 0.039
  86. Ultrastructural pathological features of cerebrovascular malformations: a preliminary report. Neurosurgery. 2000 Jun; 46(6):1454-9.
    View in: PubMed
    Score: 0.031
  87. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010 Apr 12; 207(4):881-96.
    View in: PubMed
    Score: 0.015
  88. Biology of vascular malformations of the brain. Stroke. 2009 Dec; 40(12):e694-702.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.